Division of Inflazyme Pharmaceuticals Inc.
Latest From GlycoDesign Inc.
As interest in vulnerable plaque heats up, medical device companies hope to capitalize on their earl y lead. But as vulnerable plaque shifts therapies from structural to biological, that lead many not last long. The second of a two-part series.
Eight years ago, the University of Toronto and the Innovations Foundation instituted a new policy that offered to give up ownership of most technologies to the researchers who invented them, in return for a 25% cut of the researchers' proceeds. The results of the UT's ownership policy and the IF's reorganization have been dramatic; today, UT researchers disclose about 120 inventions a year, roughly two-thirds of them medically related.
Gone are the days of random screening for new antibiotics. Now, thanks to molecular biology and genomics, start-up companies have a better sense of the mechanisms of infection. The firms think they've found novel ways to interfere with pathogens, including those resistant to current drugs.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Inflazyme Pharmaceuticals Inc.
- Senior Management
Michael Thomas , Pres. & CEO
Brian Fielding, VP, Fin. & CFO
Patricia Griffin, VP, Bus. Dev.
- Contact Info
Phone: (416) 593-6027
480 University Ave.
Toronto, M5G 1V2
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.